{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:06:05Z","timestamp":1793462765451,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.blre.2023.101040","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T02:25:00Z","timestamp":1674181500000},"page":"101040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Alice","family":"Sabinot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Pradelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Lausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2023.101040_bb0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0010","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.12677","article-title":"AL amyloidosis or multiple myeloma? An important distinction","volume":"164","author":"Falk","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101040_bb0015","article-title":"Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood","volume":"10","author":"Staron","year":"2020","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0020","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"10038","key":"10.1016\/j.blre.2023.101040_bb0025","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"14","key":"10.1016\/j.blre.2023.101040_bb0030","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart."},{"key":"10.1016\/j.blre.2023.101040_bb0035","series-title":"FDA grants accelerated approval to Darzalex Faspro for amyloidosis [Internet]","year":"2021"},{"key":"10.1016\/j.blre.2023.101040_bb0040","series-title":"Darzalex - European Medicines Agency [Internet]","year":"2021"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0045","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations. Blood","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2023.101040_bb0050","first-page":"430","article-title":"Treatment tolerability in patients with immunoglobulin light-chain amyloidosis","volume":"11","author":"Rizio","year":"2018","journal-title":"Am Health Drug Benefits"},{"issue":"7","key":"10.1016\/j.blre.2023.101040_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2021-152675","article-title":"Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients","volume":"138","author":"Palladini","year":"2021","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0065","first-page":"477","article-title":"Real-world data on patient characteristics and treatment patterns for 3000 patients with systemic al amyloidosis in Europe between 2011 and 2018:A retrospective study by the European myeloma network","volume":"5","author":"Palladini","year":"2021","journal-title":"HemaSphere."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0070","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2021-152099","article-title":"Prognostic relevance of cytogenetic chromosomal abnormalities on outcome among AL amyloidosis patients in the Netherlands","volume":"138","author":"Abbink","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0075","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/blood-2021-154277","article-title":"Autologous hematopoietic stem cell transplantation for AL amyloidosis refractory to induction therapy","volume":"138","author":"Nelson","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101040_bb0080","first-page":"21","article-title":"P-025: population-based incidence and survival of AL amyloidosis in Sweden","author":"Rosengren","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101040_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(21)02153-4","article-title":"Real-world treatment patterns, clinical outcomes, and healthcare resource utilization of individuals with light chain (AL) amyloidosis in Alberta, Canada: a population-based study","volume":"21","author":"Jimenez-Zepeda","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101040_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2021-151804","article-title":"A 40-year natural history study of overall survival and primary causes of death in systemic light chain (AL) amyloidosis","volume":"138","author":"Staron","year":"2021","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101040_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2023.101040_bb0100","first-page":"PB1657","article-title":"AL amyloidosis survival evolution in new agents era: a real life experience","author":"Rizzo","year":"2021","journal-title":"Eur Hematol Assoc"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13506129.2021.1898365","article-title":"Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study","volume":"28","author":"Zampieri","year":"2021","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0110","first-page":"467","article-title":"Pulmonary function tests reveal unrecognized lung dysfunction and have independent prognostic significance in patients with systemic al amyloidosis","volume":"5","author":"Fotiou","year":"2021","journal-title":"HemaSphere."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-140708","article-title":"First glimpse on real-world efficacy outcomes for 2000 patients with SYSTEMIC light chain AMYLOIDOSIS in Europe: a retrospective observational multicenter study by the European myeloma network","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101040_bb0120","series-title":"Real-world management of patients with systemic light chain amyloidosis in Europe: A retrospective observational multicenter study by European myeloma network (EMN)","author":"Palladini","year":"2020"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0125","first-page":"3","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis","volume":"28","author":"Kastritis","year":"2020","journal-title":"Amyloid Int J Exp Clin Invest"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.16198","article-title":"Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis","volume":"188","author":"Lilleness","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/ejh.13552","article-title":"The impact of COVID-19 in the management of AL amyloidosis and immunoglobulin deposition disease: a single-center experience","volume":"106","author":"Lee","year":"2021","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0140","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","article-title":"Prognostic restaging after treatment initiation in patients with AL amyloidosis","volume":"5","author":"Abdallah","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Revista espanola de cardiologia (English ed)"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ejh.13554","article-title":"Characterization and prognostic implication of delayed complete response in al amyloidosis","volume":"106","author":"Muchtar","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101040_bb0160","first-page":"EP1024","article-title":"A Nationwide, population-based register of systemic Al amyloidosis patients in the Netherlands; preliminary results of 205 patients diagnosed in 2017 and 2018","author":"Brink","year":"2020","journal-title":"Eur Hematol Assoc"},{"issue":"16","key":"10.1016\/j.blre.2023.101040_bb0165","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987-2019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0170","first-page":"447","article-title":"An urgent need for data to drive decision making: rationale for the Canadian registry for amyloidosis research","volume":"36","author":"Davis","year":"2020","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/ejh.13472","article-title":"Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis","volume":"105","author":"Schulman","year":"2020","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101040_bb0185","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101040_bb0195","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1182\/blood-2019-124980","article-title":"Clinical characteristics, treatment regimens and survival in elderly patients with AL amyloidosis in a tertiary referral center","volume":"134","author":"Acevedo","year":"2019","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101040_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.558","article-title":"Estimating the global epidemiology of amyloid light-chain amyloidosis with an incidence-to-prevalence model","volume":"19","author":"Zhang","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0205","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/13506129.2018.1536043","article-title":"Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016","volume":"25","author":"Rutten","year":"2018","journal-title":"Amyloid"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0215","article-title":"Incidence and prevalence of light chain amyloidosis: a population-based study","volume":"39","author":"Mohty","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0220","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm. Blood","volume":"8","author":"Gertz","year":"2018","journal-title":"Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2023.101040_bb0225","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0230","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12288-018-0937-x","article-title":"The effect and safety of Bortezomib in the treatment of AL amyloidosis: a systematic review and Meta-analysis","volume":"34","author":"Jiang","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0235","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2017","journal-title":"The Patient"},{"issue":"15","key":"10.1016\/j.blre.2023.101040_bb0245","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0250","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2016.1274971","article-title":"New and developing therapies for AL amyloidosis","volume":"18","author":"Zumbo","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"22","key":"10.1016\/j.blre.2023.101040_bb0255","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/blood.V128.22.4448.4448","article-title":"Improved survival in al AMYLOIDOSIS: a POPULATION-BASED study on 1,430 patients diagnosed in Sweden 1995-2013","volume":"128","author":"Weiss","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101040_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2015.07.201","article-title":"Interim analysis of ALCHemy \u2013 a prospective study of 1000 patients with SYSTEMIC al amyloidosis","volume":"15","author":"Wechalekar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0265","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2023.101040_bb0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood.V126.23.190.190","article-title":"Accurate risk stratification IDENTIFIES patients with AL AMYLOIDOSIS benefiting most from UPFRONT Bortezomib combinations: a study of treatment outcomes in 984 patients","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood."},{"issue":"0","key":"10.1016\/j.blre.2023.101040_bb0275","first-page":"511","article-title":"Al amyloidosis and quality of life outcomes","volume":"100","author":"Warsame","year":"2015","journal-title":"Haematologica."},{"issue":"15","key":"10.1016\/j.blre.2023.101040_bb0280","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.blre.2023.101040_bb0285","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0290","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101040_bb0295","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2023.101040_bb0300","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.V120.21.1786.1786","article-title":"Outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with novel agents and the importance of risk adapted treatment strategies","volume":"120","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2023.101040_bb0305","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.V118.21.992.992","article-title":"ALchemy - a large PROSPECTIVE \u2018real World\u2019 study of chemotherapy in AL amyloidosis","volume":"118","author":"Lane","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101040_bb0310","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0315","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/S0016-5085(10)61689-7","article-title":"Hepatic Al amyloidosis - a 10-year experience at the United Kingdom National Amyloidosis Centre (NAC)","volume":"138","author":"Sattianayagam","year":"2010","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0320","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3816\/CLML.2010.n.006","article-title":"Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece","volume":"10","author":"Michael","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101040_bb0325","first-page":"122","article-title":"Systemic AL amyloidosis with renal involvement in a region of Western France","volume":"17","author":"Moumas","year":"2010","journal-title":"Amyloid."},{"issue":"9","key":"10.1016\/j.blre.2023.101040_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2017.08.927","article-title":"Health-related quality of life and rates of emergency room visits and hospitalization in patients with al amyloidosis: a prospective analysis","volume":"20","author":"McCausland","year":"2017","journal-title":"Value Health"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0335","first-page":"4733","article-title":"Associations between socioeconomic status and health-related quality of life in patients with AL amyloidosis","volume":"130","author":"McCausland","year":"2017","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0564-2","article-title":"The burden of amyloid light chain amyloidosis on health-related quality of life","volume":"12","author":"Bayliss","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0345","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13506129.2016.1208081","article-title":"Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients","volume":"23","author":"Shu","year":"2016","journal-title":"Amyloid"},{"issue":"22","key":"10.1016\/j.blre.2023.101040_bb0350","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood.V128.22.3586.3586","article-title":"Changes in health-related quality of life corresponding to hematologic responses to treatment in AL amyloidosis","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0355","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/joa3.12376","article-title":"Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014","volume":"36","author":"Isath","year":"2020","journal-title":"J Arrhythm"},{"key":"10.1016\/j.blre.2023.101040_bb0360","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CEOR.S207127","article-title":"Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States","volume":"11","author":"Quock","year":"2019","journal-title":"CEOR"},{"issue":"6","key":"10.1016\/j.blre.2023.101040_bb0365","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/cer-2017-0100","article-title":"Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data","volume":"7","author":"Quock","year":"2018","journal-title":"J Comp Effect Res"},{"issue":"8","key":"10.1016\/j.blre.2023.101040_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2017.07.365","article-title":"Trends of cardiac transplantation in cardiac AMYLOIDOSIS in the United States FROM 2008\u20132014","volume":"23","author":"Taduru","year":"2017","journal-title":"J Card Fail"},{"issue":"18","key":"10.1016\/j.blre.2023.101040_bb0375","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0380","article-title":"The amyloidosis forum: a public private partnership to advance drug development in al amyloidosis","volume":"15","author":"Lousada","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0385","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2010.03215.x","article-title":"Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study","volume":"18","author":"Matsuda","year":"2011","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4081\/itjm.2019.1149","article-title":"Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians","volume":"13","author":"Angelini","year":"2019","journal-title":"Italian J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0395","first-page":"373","article-title":"Hiding in plain sight: cardiac amyloidosis, an emerging epidemic","volume":"36","author":"Di Giovanni","year":"2020","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0400","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.blre.2023.101040_bb0405","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101040_bb0410","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjh.12973","article-title":"Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens","volume":"166","author":"Mahmood","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0415","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-019-0400-5","article-title":"Prognostic restaging at the time of SECOND-LINE therapy in patients with al amyloidosis","volume":"33","author":"Hwa","year":"2019","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0420","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101040_bb0425","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137036","article-title":"The prognostic importance of the 6-minute walk test in AL amyloidosis","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101040_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100636","article-title":"New developments in diagnosis, risk assessment and management in systemic amyloidosis","volume":"40","author":"Vaxman","year":"2020","journal-title":"Blood Rev"},{"issue":"5","key":"10.1016\/j.blre.2023.101040_bb0440","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer"},{"issue":"6","key":"10.1016\/j.blre.2023.101040_bb0445","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","article-title":"Disease burden of systemic light-chain amyloidosis: a systematic literature review","volume":"33","author":"Lin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"23","key":"10.1016\/j.blre.2023.101040_bb0450","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101040_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2017.1411796","article-title":"Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis","volume":"25","author":"Hari","year":"2018","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.blre.2023.101040_bb0460","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.blre.2023.101040_bb0465","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","article-title":"Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis","volume":"35","author":"Szalat","year":"2021","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.blre.2023.101040_bb0470","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/CCO.0000000000000881","article-title":"Advances in the treatment of light chain amyloidosis","volume":"34","author":"Palladini","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101040_bb0475","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000681","article-title":"Summary of the EHA-ISA working group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis","volume":"6","author":"Sanchorawala","year":"2022","journal-title":"Hemasphere."},{"key":"10.1016\/j.blre.2023.101040_bb0480","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"1-15","author":"Wechalekar","year":"2022","journal-title":"Amyloid."},{"issue":"4","key":"10.1016\/j.blre.2023.101040_bb0485","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/jha2.562","article-title":"Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: a population-based cohort study","volume":"3","author":"Jimenez-Zepeda","year":"2022","journal-title":"eJHaem."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:29:16Z","timestamp":1759436956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":96,"alternative-id":["S0268960X23000012"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101040","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101040"}}